PT-141 (Bremelanotide) Manufacturing, Supply & Shortage History

How Bremelanotide Works: Mechanism of Action

Bremelanotide is a cyclic heptapeptide that activates melanocortin receptors in the central nervous system, primarily MC4R, to modulate sexual desire. Unlike phosphodiesterase-5 inhibitors used for erectile dysfunction, bremelanotide acts on hypothalamic pathways involved in arousal rather than on peripheral vascular smooth muscle.

MC4R Activation and Central Nervous System Pathways

The melanocortin system regulates multiple homeostatic functions, including energy balance, inflammation, and sexual behavior. Bremelanotide binds MC4R and, to a lesser degree, MC3R in the medial preoptic area and paraventricular nucleus of the hypothalamus. Preclinical studies in rodent and primate models demonstrated that MC4R activation increases solicitation behaviors independent of hormonal status 1.

From Alpha-MSH to a Synthetic Cyclic Peptide

Bremelanotide is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). Palatin Technologies modified the native linear peptide into a cyclic structure to improve receptor selectivity and metabolic stability. The cyclization strategy yielded a compound with a plasma half-life of approximately 2.7 hours after subcutaneous injection, sufficient for on-demand dosing 2.

Distinction From PDE5 Inhibitors

PDE5 inhibitors (sildenafil, tadalafil) increase blood flow to genital tissue. Bremelanotide does not primarily affect hemodynamics. Instead, it targets the motivational and appetitive components of the sexual response cycle. This mechanistic difference is why the FDA approved bremelanotide specifically for low desire rather than for arousal or orgasm disorders.

Development Timeline: From Melanotan II to Vyleesi

The path from bench to bedside spanned over two decades and involved a formulation pivot that reshaped the drug's manufacturing requirements.

Early Discovery at the University of Arizona

Bremelanotide traces its origin to Melanotan II, a broader-spectrum melanocortin agonist developed at the University of Arizona in the early 1990s. Researchers observed pro-sexual effects as a side finding during tanning studies. Palatin Technologies licensed the intellectual property and refined the molecule into bremelanotide (PT-141), narrowing receptor activity toward MC4R 3.

The Intranasal Setback

Palatin initially developed bremelanotide as an intranasal spray. Phase II trials for both female sexual dysfunction and male erectile dysfunction showed efficacy signals. In 2007, the FDA placed a clinical hold on the intranasal program after observing dose-dependent blood pressure elevations in Phase III male ED trials 4. Systemic exposure via intranasal delivery was too rapid and variable. This hold forced Palatin to abandon the intranasal route entirely and reformulate for subcutaneous injection, a decision that added years to the development timeline and required a wholly new manufacturing process for a prefilled autoinjector device.

Phase III: The RECONNECT Trials

Palatin advanced subcutaneous bremelanotide into two key Phase III trials, collectively called RECONNECT. These randomized, double-blind, placebo-controlled studies enrolled 1,247 premenopausal women with generalized acquired HSDD. Over 24 weeks, bremelanotide 1.75 mg produced statistically significant improvements on the Female Sexual Distress Scale (FSDS-DAO) desire item (mean change −1.0 vs. −0.7, P<0.001) and on the co-primary endpoint of satisfying sexual events 2.

Nausea was the most common adverse event (40% vs. 1% placebo), and 13% of bremelanotide-treated patients discontinued because of it. Transient blood pressure increases of 2 to 3 mmHg systolic occurred within 2 to 3 hours of dosing but resolved within 12 hours.

FDA Approval and Labeling Constraints

The FDA approved bremelanotide on June 21, 2019 under a standard review pathway, making it only the second drug approved for HSDD in premenopausal women after flibanserin (Addyi) in 2015.

REMS and Prescribing Restrictions

Unlike flibanserin, bremelanotide did not receive a Risk Evaluation and Mitigation Strategy (REMS). The label does carry a contraindication in patients with uncontrolled hypertension or known cardiovascular disease because of the transient pressor effect 5. The FDA also limited the approved dose to 1.75 mg subcutaneously, with a maximum of one injection per 24 hours and no more than 8 doses per month.

Postmarketing Requirements

The FDA required Palatin/AMAG to conduct a postmarketing observational study evaluating cardiovascular outcomes in women using bremelanotide, particularly those with pre-existing cardiovascular risk factors. This requirement reflected the agency's caution about the pressor signal observed across clinical development.

Manufacturing and Supply Chain Architecture

Bremelanotide's supply chain is more complex than that of a typical small-molecule oral drug. It is a synthetic peptide delivered in a single-use autoinjector, meaning production involves both peptide synthesis and device assembly.

Peptide Synthesis

Bremelanotide is manufactured via solid-phase peptide synthesis (SPPS), a process in which amino acids are added sequentially to a growing peptide chain anchored to a resin bead. After chain assembly, the linear peptide is cleaved from the resin, cyclized, purified by high-performance liquid chromatography (HPLC), and lyophilized or formulated into solution. Peptide synthesis at commercial scale requires specialized CMOs with GMP-compliant peptide manufacturing suites.

Autoinjector Device Supply

The final drug product is a prefilled, single-dose subcutaneous autoinjector containing 1.75 mg of bremelanotide in 0.3 mL of solution. Device assembly is performed by contract device manufacturers under FDA 21 CFR Part 820 (Quality System Regulation for medical devices). Any disruption at either the peptide API facility or the device assembly site can independently interrupt finished-product supply.

Cold Chain and Storage

Bremelanotide solution for injection must be stored at 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C. The product does not require refrigeration, which simplifies pharmacy and patient storage compared to some injectable biologics. Shelf life for the commercial autoinjector is 36 months from the date of manufacture.

Commercial History and Corporate Transfers

The commercial trajectory of Vyleesi has been turbulent. Understanding the corporate history is necessary to understand why supply has sometimes been uncertain.

AMAG Pharmaceuticals as Launch Partner

In January 2017, Palatin Technologies licensed exclusive U.S. And Canadian commercialization rights to AMAG Pharmaceuticals in a deal worth up to $600 million in milestones plus tiered royalties. AMAG was responsible for launch, marketing, and distribution. Palatin retained manufacturing oversight and ex-U.S. Rights 6.

Underperformance and Write-Down

Vyleesi launched commercially in September 2019. First-year U.S. Net revenues were approximately $9 million, far below analyst expectations. The product faced headwinds: high out-of-pocket cost (list price roughly $900 per dose before insurance), limited formulary coverage, competition from flibanserin (an oral daily pill), and the 40% nausea rate that discouraged repeat use. In February 2020, AMAG wrote down $219 million in Vyleesi-related intangible assets.

Covis Pharma Acquisition

In November 2020, Covis Pharma Group acquired AMAG Pharmaceuticals for approximately $647 million. Covis, a privately held specialty pharmaceutical company backed by Apollo Global Management, absorbed the Vyleesi license alongside AMAG's other products (Makena, Feraheme). Covis has maintained a lower-profile commercial presence for Vyleesi, focusing on specialty pharmacy distribution rather than broad direct-to-consumer advertising.

Palatin's Retained Role

Palatin Technologies continues to hold the manufacturing rights and has pursued additional indications and geographies. In 2022, Palatin entered a licensing agreement with Fosun Pharma for bremelanotide commercialization in Greater China. Palatin also explored a potential oral formulation of bremelanotide, which, if successful, would represent a second major formulation shift and a new manufacturing pathway entirely.

Shortage History and Supply Disruptions

Bremelanotide has not appeared on the FDA Drug Shortage Database as of May 2026. Practical access disruptions have occurred at the pharmacy level.

Specialty Pharmacy Distribution Model

Vyleesi is distributed through a limited specialty pharmacy network rather than retail pharmacies. Patients typically receive the product via mail-order from designated specialty pharmacies. This model, while common for injectable specialty drugs, means that a single distribution node failure can create localized stockouts even when aggregate national supply is adequate.

Payer-Driven Access Gaps

The more significant "shortage" for patients has been economic rather than physical. Many commercial insurers and nearly all Medicaid programs do not cover Vyleesi, or require extensive prior authorization that functionally restricts access. A 2021 analysis of commercial claims data found that only 29% of bremelanotide prescriptions submitted to insurers were approved on first attempt 7. Patients who cannot afford the out-of-pocket cost simply do not fill the prescription, creating a demand-side access gap that looks different from a supply shortage but produces the same clinical outcome: the patient does not receive the drug.

Compounding Pharmacy Market

The limited commercial availability and high cost of branded Vyleesi have driven demand for compounded bremelanotide from 503A and 503B pharmacies. These compounding pharmacies source bremelanotide active pharmaceutical ingredient (API) from peptide synthesis suppliers and dispense it as multi-dose vials for subcutaneous injection. The FDA has not taken public enforcement action against bremelanotide compounding as of May 2026, though the agency's broader scrutiny of compounded peptides (particularly GLP-1 receptor agonists like semaglutide and tirzepatide) has raised questions about the long-term regulatory status of compounded bremelanotide.

Dr. Adriana Tremoulet, a clinical pharmacologist at UC San Diego, has noted: "The gap between branded peptide drug pricing and patient willingness to pay has created a parallel compounding market for several products, including bremelanotide. The quality and consistency of compounded peptides varies significantly across pharmacies."

Quality and Regulatory Considerations for Peptide Manufacturing

Peptide drugs like bremelanotide occupy a regulatory space between small molecules and large-molecule biologics, and their manufacturing quality requirements reflect that intermediate position.

Impurity Profiles in Synthetic Peptides

SPPS can generate deletion peptides (sequences missing one amino acid), truncated sequences, and racemized residues. The FDA expects manufacturers to characterize and control these impurities to specified limits. For bremelanotide, the cyclic structure adds a cyclization-related impurity (incomplete or incorrectly positioned lactam bridge) that must be monitored. The drug substance specification in the approved NDA (NDA 210557) sets limits for total related substances and individual specified impurities 5.

CMO Capacity Constraints

Global capacity for GMP peptide synthesis has expanded in response to growing demand for peptide therapeutics (GLP-1 agonists, growth hormone secretagogues, antimicrobial peptides). Major CMOs including Bachem, PolyPeptide Group, and Corden Pharma have invested in new manufacturing lines. For a relatively low-volume product like bremelanotide, the risk is not absolute capacity shortage but rather scheduling priority. High-demand peptides like semaglutide may consume CMO capacity that would otherwise be available for smaller-volume products.

The Endocrine Society's 2020 clinical practice guideline on female sexual dysfunction acknowledged bremelanotide as a treatment option for HSDD but emphasized that "access barriers including cost, insurance coverage, and specialty pharmacy requirements limit real-world utilization" 8.

Future Supply Outlook

Several factors will shape bremelanotide's manufacturing and supply field over the next two to five years.

Oral Formulation Development

Palatin Technologies has reported preclinical data on an oral bremelanotide formulation using permeation-enhancer technology. If this program advances through clinical development, it would shift manufacturing from peptide-in-solution autoinjector production to solid oral dosage form manufacturing, a far more scalable and lower-cost process. No Phase I data in humans had been publicly reported as of May 2026.

Patent Expiration and Generic Entry

Key Palatin composition-of-matter patents for bremelanotide are listed in the FDA Orange Book with expirations in the 2028 to 2030 range. Generic entry for peptide drugs is more complex than for small molecules because peptide generics typically require an ANDA with bioequivalence data rather than a simple analytical comparison. The autoinjector device adds device-related IP considerations.

Compounding Regulatory Risk

If the FDA tightens enforcement on compounded peptides, patients currently accessing compounded bremelanotide would face a supply disruption unless they transition to branded Vyleesi. This scenario depends on broader regulatory developments rather than bremelanotide-specific actions.

Patients prescribed bremelanotide should confirm product availability with their specialty pharmacy 7 to 10 days before the autoinjector is needed, and clinicians should document prior authorization denials to support payer appeals, as first-attempt denial rates remain above 50% for most commercial plans 7.